Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN 5% vs AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy via glycolysis and oxidative phosphorylation.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion: 1-1.5 g amino acids/kg/day (equivalent to 28-43 mL/kg/day of Aminosyn II 3.5% in D5W). Rate: infuse via central line at ≤100 mL/hour; peripheral line at ≤125 mL/hour. Adjust based on nitrogen balance and metabolic response.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Not applicable as a mixture; individual components have varying half-lives. Dextrose: rapid distribution, half-life <1 hour. Amino acids: half-life of infused amino acids is short (minutes) due to metabolism.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Aminosyn II 3.5% in Dextrose 5% contains amino acids and dextrose. Amino acids are metabolized; negligible renal excretion of intact amino acids. Dextrose is metabolized. No biliary/fecal elimination of intact drug.
Category C
Category C
Amino Acid Solution
Amino Acid Solution